Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Noxafil Contraindicated for Combined Use with Lonasen, Belsomra
The Ministry of Health, Labor and Welfare (MHLW) issued a notification on December 17, ordering label revisions to contraindicate MSD’s antifungal agent Noxafil (posaconazole) for its combination use with blonanserin and suvorexant, respectively. According to the regulators, it was estimated…
To read the full story
Related Article
- PMDA Reviewing Safety Risk of Imusera/Gilenya
November 29, 2021
REGULATORY
- Pharma Urges Pricing Rewards to Bolster Japan’s Drug Discovery Strength
September 24, 2026
- New Digital Minister Furukawa Pledges Push for Healthy Longevity
September 24, 2026
- MHLW Eyes Higher Long-Term Care Premiums for Wealthier Seniors
September 24, 2026
- Nippon Ishin’s Urano Named Senior Vice Health Minister in Takaichi Cabinet
September 24, 2026
- Ueno Vows to Advance Drug Innovation, Advanced Medicine in 2nd Term
September 24, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…